Retrospective evaluation of the clinicopathological features of this sample revealed a triple-negative phenotype, an intense immune infiltrate (tumor-infiltrating lymphocytes, TILs = 90%), and a lack of MLH1-PMS2 expression (Additional file 4: Fig. S3). The gene discussed is PMS2; the disease is neoplasm.